69 related articles for article (PubMed ID: 7506904)
1. Expression of the tumor marker D-galactose-beta-[1-->3]-N-acetyl-D-galactosamine by premalignant and malignant prostate.
Shamsuddin AM; Beasley WM
Arch Pathol Lab Med; 1994 Jan; 118(1):48-51. PubMed ID: 7506904
[TBL] [Abstract][Full Text] [Related]
2. Common expression of the tumor marker D-galactose-beta-[1-->3]-N-acetyl-D-galactosamine by different adenocarcinomas: evidence of field effect phenomenon.
Shamsuddin AM; Tyner GT; Yang GY
Cancer Res; 1995 Jan; 55(1):149-52. PubMed ID: 7805025
[TBL] [Abstract][Full Text] [Related]
3. [Various immunohistochemical markers of precancer and variants of prostate cancer].
Romanenko AM; Vorob'eva LR
Arkh Patol; 1995; 57(4):38-41. PubMed ID: 8526754
[TBL] [Abstract][Full Text] [Related]
4. In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein D expression in benign and malignant prostate tissues.
Rodríguez JC; Díaz M; González LO; Sánchez J; Sánchez MT; Merino AM; Vizoso F
Int J Surg Investig; 2000; 2(4):319-26. PubMed ID: 12678535
[TBL] [Abstract][Full Text] [Related]
6. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
7. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
8. Detection of the tumor marker D-galactose-beta-(1-->3)-N-acetyl-D-galactosamine in colonic cancer and precancer.
Xu H; Sakamoto K; Shamsuddin AM
Arch Pathol Lab Med; 1992 Nov; 116(11):1234-8. PubMed ID: 1332646
[TBL] [Abstract][Full Text] [Related]
9. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens.
Huang D; Casale GP; Tian J; Wehbi NK; Abrahams NA; Kaleem Z; Smith LM; Johansson SL; Elkahwaji JE; Hemstreet GP
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1371-81. PubMed ID: 17623804
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of galactose oxidase-Schiff reaction in the detection of carcinoma and precancerous lesions of large intestine].
Qin J; Zhang Q; Fang X
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):157-9. PubMed ID: 10743086
[TBL] [Abstract][Full Text] [Related]
11. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
12. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate.
Botticelli AR
Pathologica; 1994 Apr; 86(2):128-41. PubMed ID: 7524011
[TBL] [Abstract][Full Text] [Related]
13. Changes in keratin expression during the development of benign prostatic hyperplasia.
Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
[TBL] [Abstract][Full Text] [Related]
14. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
15. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
17. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.
Chandler JD; Williams ED; Slavin JL; Best JD; Rogers S
Cancer; 2003 Apr; 97(8):2035-42. PubMed ID: 12673735
[TBL] [Abstract][Full Text] [Related]
18. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
Merseburger AS; Hennenlotter J; Simon P; Müller CC; Kühs U; Knüchel-Clarke R; Moul JW; Stenzl A; Kuczyk MA
Oncol Rep; 2006 Jul; 16(1):79-83. PubMed ID: 16786126
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue.
Köllermann J; Helpap B
Am J Clin Pathol; 2001 Jul; 116(1):115-21. PubMed ID: 11447740
[TBL] [Abstract][Full Text] [Related]
20. Over expression of ID-1 in prostate cancer.
Ouyang XS; Wang X; Lee DT; Tsao SW; Wong YC
J Urol; 2002 Jun; 167(6):2598-602. PubMed ID: 11992094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
